Jun 22,2021

Peer-Reviewed Study Suggests Nerivio Effective for Treatment of Acute Menstrual Migraine Headache

Theranica, a prescribed digital therapeutics company developing advanced electroceuticals for migraine and other pain conditions, announced that a new peer-reviewed study published in Pain and Therapy demonstrates the efficacy of Nerivio in treating menstrual migraine. Menstrual migraine, a sub-type of migraine, is often more painful, more disabling and of longer duration compared to other types of migraine.

CLINICAL STUDY

#connected device

#mobile app

View Analyst & Ambassador Comments
Go to original news
Oct 08,2021

Limbix Presents Data Demonstrating Treatment with SparkRx Digital Therapeutic

Today, Limbix, a prescription digital therapeutic company developing mental health treatments for adolescents, announced positive results from a virtual randomized controlled trial of SparkRx, the company’s digital therapeutic for adolescents with symptoms of depression. For participants that completed the program as recommended (n = 83), SparkRx led to a statistically significant reduction in depression symptoms compared to an active control app (p = 0.023) and a 21% remission rate compared to a 4% remission rate for control at the end of treatment. Treatment response rates were 29% and 16%, respectively, for SparkRx and control. ‍

CLINICAL STUDY

#cbt

View Analyst & Ambassador Comments
Go to original news
Oct 15,2021

JAMA Study of over 28,000 Participants Finds 84% of Hello Heart Users Reduced Blood Pressure Over Three Years

Hello Heart, the only digital therapeutics company to focus exclusively on heart disease, today announced that its digital health application for blood pressure management can achieve and maintain lower blood pressure over time, even for those most at risk for heart disease. The results, published in JAMA Network Open, a peer-reviewed journal of the American Medical Association, showed that over 84 percent of participants with stage II hypertension achieved a reduction in their systolic blood pressure, which was maintained over three years.

CLINICAL STUDY

#connected device

#mobile app

View Analyst & Ambassador Comments
Go to original news
Oct 18,2021

MODIA™ paper published in the Journal of Medical Internet Research Mental Health

Orexo AB (publ.), (STO:ORX) (OTCQX:ORXOY) today announced the publication of a manuscript, “A Personalized, Interactive, Cognitive-Behavioral Therapy-Based Digital Therapeutic (MODIA™) for Adjunctive Treatment of Opioid Use Disorder: Development Study,” in the Journal of Medical Internet Research (JMIR) Mental Health. MODIA™ was developed by Orexo in collaboration with GAIA AG, and, in July, Orexo was pleased to announce the enrollment of the first participant in a clinical evaluation of MODIA™ for the treatment of opioid use disorder (OUD) as part of a clinician-supervised medication assisted treatment (MAT) program.

CLINICAL STUDY

#cbt

View Analyst & Ambassador Comments
Go to original news
Oct 18,2021

Peer-Reviewed Published Study Provides Further Evidence for the Safety and Efficacy of Nerivio® in Patients with Chronic Migraine

Theranica, a prescribed digital therapeutics company developing advanced electroceuticals for migraine and other pain conditions, announced today a new peer-reviewed article, with the publication of a chronic migraine study by Pain Reports. The prospective, multi-center, open-label trial (NCT04194008), evaluated the efficacy and safety of remote electrical neuromodulation (REN) for the acute treatment of migraine in chronic migraine patients. Results from the study's 99 chronic migraine participants demonstrated favorable efficacy of REN, with nearly 60% of the participants experiencing pain relief at 2 hours after the treatment, and nearly 65% of those experiencing sustained pain relief even 24 hours post treatment.

CLINICAL STUDY

#connected device

#mobile app

View Analyst & Ambassador Comments
Go to original news
Nov 03,2021

Pear Therapeutics Announces Publication Showing Cost Savings And Decreased Hospital Encounters For Opioid Use Disorder Patients

Pear Therapeutics, Inc., today announced results from an analysis of real-world data evaluating healthcare resource utilization (HCRU) for reSET-O®. Results from the analysis, published in ClinicoEconomics and Outcomes Research, found that total hospital facility and clinician services costs for patients treated with an 84-day prescription of reSET-O (n=444) were $8,733 compared to $11,441 for patients who were prescribed but did not use or engage with reSET-O (n=64).

CLINICAL STUDY

#pdt

View Analyst & Ambassador Comments
Go to original news
Nov 09,2021

Reductions in healthcare resource utilization among patients with COPD enrolled in a digital health intervention

In a recent study presented at the European Respiratory Society International Congress 2021, Propeller, in partnership with Desert Oasis Healthcare, evaluated the effect of a 6-month digital health intervention on healthcare resource utilization (HCRU) and medication use in patients with COPD. Fifty-six patients with COPD were enrolled by their clinical pharmacist in Propeller’s digital health platform. Research showed a 48% relative reduction in all-cause HCRU and stable controller medication adherence (61.5% by the last week) among enrolled patients.

CLINICAL STUDY

#mobile app

#connected device

View Analyst & Ambassador Comments
Go to original news
Nov 30,2021

Digital health solutions improves asthma self-management. What about COPD?

Digital health solutions are beginning to transform chronic respiratory disease care. However, far fewer studies have been conducted to understand how the use of digital health tools can impact those with COPD. To help address this, the COPD Foundation and GSK collaborated with Propeller to conduct a 24-week pilot study with a COPD population. The study aims to determine the extent to which people with COPD voluntarily engage with a digital health solution (the Propeller platform – an inhaler sensor and mobile app) and how it impacted their medication adherence and rescue inhaler use over time.

CLINICAL STUDY

#mobile app

#connected device

View Analyst & Ambassador Comments
Go to original news
Dec 15,2021

Digital Therapy for Prenatal Insomnia May Prevent Postpartum Depression

A digital version of cognitive behavioral therapy, or dCBT, that previously had been shown to reduce insomnia during pregnancy may also prevent postpartum depression and reduce insomnia and anxiety in women up to six months after they give birth, according to a new study by researchers at UC San Francisco. The study, which appears in the current issue of the journal Sleep, is unique in showing that non-depressed women who received dCBT (Sleepio, by Big Health) for insomnia during pregnancy also slept better and had less depression several months into the postpartum period. The study is a follow-up to research that appeared January 2020 in JAMA Psychiatry showing the treatment reduced insomnia, depression, and anxiety symptoms during pregnancy.

CLINICAL STUDY

#mobile app

#cbt

View Analyst & Ambassador Comments
Go to original news
Dec 15,2021

Largest Randomized Controlled Trial in the Digital MSK Industry Validates That Kaia Health Cuts Costs by 80%

Kaia Health, the digital therapeutics company on a mission to democratize access to high-quality healthcare, today announced clinical trial results demonstrating that its musculoskeletal (MSK) solution reduces costs by 80% when compared with standard-of-care treatments. The findings come from the ongoing Rise-uP randomized controlled trial (RCT), the largest RCT to date in the digital MSK industry.

CLINICAL STUDY
View Analyst & Ambassador Comments
Go to original news
Subscribe to CLINICAL STUDY